Pharma BD Deal Intelligence
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced on September 17, 2026 the acquisition of privately held Marea Therapeutics in an all-stock transaction alongside a concurrent USD 225 million private placement. On a fully-diluted as-converted basis, pre-acquisition Marea shareholders hold approximately 59.54 percent of the combined company, private placement investors approximately 38.07 percent, and pre-acquisition Lisata shareholders approximately 2.39 percent -- a structure the trade press characterizes as a reverse merger that takes Marea public through the Lisata listing. The private placement was led by RA Capital Management, Forbion, Third Rock Ventures, Alpha Wave, Perceptive Advisors and Sofinnova Investments, priced at approximately USD 1.4914 per common-equivalent share. The combined company retains the Lisata Therapeutics name and LSTA ticker and pivots from Lisata''s prior oncology focus to Marea''s cardioendocrine pipeline: MAR001 (also referenced as MAR005), an anti-ANGPTL4 monoclonal antibody in Phase 2b for severe hypertriglyceridemia, and MAR002, a growth hormone receptor antagonist antibody in Phase 2 for acromegaly, with topline readouts guided to Q4 2027. No aggregate transaction consideration was disclosed in the announcement; a third-party financial data aggregator has reported an implied value of approximately USD 240 million, which is not corroborated by the primary release and is therefore not recorded as the deal value. NOTE: ingested at pending_review pending enrichment.
← Browse all deals · How we score deals
More: 2026 deals